Month: March 2022

POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update

Written by Customer Service on March 25, 2022. Posted in Earnings Releases And Operating Results.

Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of SPLASH trial ongoing, top line data expected mid-2023 Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022 Indianapolis radiopharmaceutical manufacturing facility operational and supplying doses of PNT2002 to support the SPLASH trial – view the facility online at manufacturing.pointbiopharma.com INDIANAPOLIS, March 25, 2022 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided...

HydroGraph Clean Power to attend CEM AlphaNorth Capital Event

Written by Customer Service on March 25, 2022. Posted in Public Companies.

VANCOUVER, British Columbia, March 25, 2022 (GLOBE NEWSWIRE) — HydroGraph Clean Power Inc. (HG.CN) (OTCMKTS:HGCPF) (the “Company” or “HydroGraph”), a commercial manufacturer of high-quality nanomaterials and alternative-energy fuels, today announced that it will conduct one-on-one meetings with investors at the CEM AlphaNorth Capital Event in Nassau, Bahamas from March 25-27, 2022. HydroGraph manufactures strategic products such as the super-material graphene used in dozens of industries, and alternative-energy fuels in high-demand such as hydrogen, all through an industry-leading patented technology that achieves the highest quality, a low cost, and, unlike conventional processes, is environmentally friendly. The technology — the Hyperion detonation system — is ideal for commercial scale: compact and modular, the small footprint...

Brompton North American Financials Dividend ETF Risk Rating Improvement

Written by Customer Service on March 25, 2022. Posted in Public Companies.

TORONTO, March 25, 2022 (GLOBE NEWSWIRE) — (TSX: BFIN, BFIN.U) Brompton North American Financials Dividend ETF (the “Fund”) announces a change to the risk rating of the Fund. The change to the Fund’s risk rating is a result of ongoing review of the risk rating and not as a result of any changes to the Fund’s investment objectives, strategies, restrictions or management of the Fund. The decrease in the risk rating was a result of decreased volatility experienced in the financials sector.Previous Risk Rating New Risk RatingMedium to High MediumAbout Brompton FundsFounded in 2000, Brompton Funds Limited (“Brompton”) is an experienced investment fund manager with income focused investment solutions including Toronto Stock Exchange listed closed-end funds and exchange-traded funds. For further information, please contact your...

Form 8.3 – [CareTech Holdings plc – 24 03 2022] – (CGWL)

Written by Customer Service on March 25, 2022. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree CARETECH HOLDINGS PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position...

Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease

Written by Customer Service on March 25, 2022. Posted in Public Companies.

CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2Graft-versus-host disease (GvHD) is a serious and debilitating complication of stem cell transplants, with no established standard of care for patients who do not adequately respond to first-line steroid treatment3,4Nearly half of patients experience either acute or chronic GvHD, or both, following allogeneic transplants3,4Basel, March 25, 2022 — Novartis announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Jakavi® (ruxolitinib) for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease...

Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe

Written by Customer Service on March 25, 2022. Posted in Public Companies.

Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment optionCHMP opinion based on Phase II global ELARA trial demonstrating high response rates in heavily pretreated patients; 69% experienced a complete response, with an 86% overall response rate and a remarkable safety profile1If approved, Kymriah may offer an effective, new treatment option to patients with advanced follicular lymphoma to break the cycle of remittent and relapsing diseasesWell-established Kymriah safety profile and post-treatment protocols allow for flexibility to administer in the outpatient setting, reducing the burden of therapy for patients and their healthcare teams across Europe1,2 Basel, March 25, 2022 — Novartis announced today that the Committee for Medicinal Products...

Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting

Written by Customer Service on March 25, 2022. Posted in Public Companies.

Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with no associated tachyphylaxisTapinarof was well-tolerated in sensitive skin and intertriginous areas with majority of patients experiencing no irritation for up to 52 weeks Tapinarof was well tolerated with long term use and demonstrated continued and durable improvement in quality of lifeLONG BEACH, Calif., and BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) — Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced Phase 3 PSOARING 3 long-term extension study results demonstrating durable improvements across efficacy outcomes, quality of life measures, and tolerability...

Delcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update

Written by Customer Service on March 25, 2022. Posted in Earnings Releases And Operating Results.

NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter and full-year ended December 31, 2021. Recent Business Highlights During and since the fourth quarter, Delcath:Reported updated positive phase 3 FOCUS trial results for HEPZATO™ Kit (melphalan hydrochloride for injection/hepatic delivery system) for the treatment of patients with unresectable liver-dominant metastatic ocular melanoma, including initial survival data analysis Confirmed guidance for the mid-year Class 2 resubmission of the NDA to FDA Resumed direct responsibility for sales, marketing, and distribution activities for the CHEMOSAT® Hepatic Delivery...

Marathon Gold Announces 2021 Fourth Quarter and Year-End Results

Written by Customer Service on March 25, 2022. Posted in Earnings Releases And Operating Results.

TORONTO, March 25, 2022 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) today announces its financial results for the fourth quarter and year ending December 31, 2021 and provides an update on the Company’s activities at the Valentine Gold Project (the “Project”) in the central region of Newfoundland and Labrador (“NL”). Fourth Quarter HighlightsAt December 31, 2021, the Company had cash and cash equivalents of $87.2 million, leaving it well positioned to execute on its permitting, development, and exploration activities at the Project; During the fourth quarter of 2021, a total of 19,497 metres of exploration drilling was completed in 73 holes primarily at the Berry, Victory and Sprite Deposits. In total during 2021, Marathon completed 74,004 metres of drilling, successfully completing its...

Fairfax India Holdings Corporation: Annual Shareholders’ Meeting Update

Written by Customer Service on March 25, 2022. Posted in Public Companies.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, March 25, 2022 (GLOBE NEWSWIRE) — Fairfax India Holdings Corporation (“Fairfax India” or the “Company”) (TSX: FIH.U) announces that it will be hosting its annual shareholders’ meeting both in-person and virtually, as originally announced, on Thursday, April 21, 2022. Our expectation is that many of the Presidents of our portfolio companies will be attending the meeting in-person to greet our guests and to answer any questions. For those travelling to attend the meeting, we are pleased to share that, effective April 1, 2022, fully vaccinated travellers arriving to Canada will no longer need to provide pre-entry COVID-19 test results. Fairfax India will advise of further details on the meeting, including how to send questions in advance,...

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

Month: March 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals